Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anvumetostat Alone and in Combination With Docetaxel in Advanced MTAP-null Solid Tumors
NCT05094336Phase 2Active, not recruiting
- Sponsor
- Amgen
- Start
- Feb 2022
- Primary completion
- Nov 2026
- Modality
- Small Molecules
- Countries
- 14
01
Overview
A Phase 2 trial of anvumetostat in solid tumor, sponsored by Amgen. Started Feb 2022; status: active, not recruiting.
02
Drugs
anvumetostat
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT05094336.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05094336.